Bevacizumab in Addition to Palliative Chemotherapy for Patients With Peritoneal Carcinomatosis of Colorectal Origin: A Nationwide Population-Based Study

Micro-Abstract Data on the use and effect of bevacizumab, in addition to palliative chemotherapy, are currently lacking for patients with colorectal cancer presenting with peritoneal carcinomatosis (PC). The present study involved 1235 patients with colorectal PC receiving only palliative systemic t...

Full description

Saved in:
Bibliographic Details
Published in:Clinical colorectal cancer 2016-06, Vol.15 (2), p.e41-e46
Main Authors: Razenberg, Lieke G.E.M, van Gestel, Yvette R.B.M, Lemmens, Valery E.P.P, de Hingh, Ignace H.J.T, Creemers, Geert-Jan
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adenocarcinoma - secondary
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab - administration & dosage
Colorectal cancer
Colorectal Neoplasms - pathology
Female
Gastroenterology and Hepatology
Hematology, Oncology and Palliative Medicine
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Netherlands
Palliative Care
Palliative systemic therapy
Peritoneal metastases
Peritoneal Neoplasms - drug therapy
Peritoneal Neoplasms - secondary
Proportional Hazards Models
Registries
Retrospective Studies
Synchronous
Targeted therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract Data on the use and effect of bevacizumab, in addition to palliative chemotherapy, are currently lacking for patients with colorectal cancer presenting with peritoneal carcinomatosis (PC). The present study involved 1235 patients with colorectal PC receiving only palliative systemic therapy. Bevacizumab was prescribed to 436 patients (35%) and was associated with an improved median overall survival (11 months).
ISSN:1533-0028
1938-0674
DOI:10.1016/j.clcc.2015.12.006